Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.
about
Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerIntravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancerHigh-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG ShortageManagement of carcinoma in situ of the bladder: best practice and recent developmentsBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseBacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease[Therapy and follow-up of bladder cancer].Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.Southwest Oncology Group studies in bladder cancer.Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.Is intravesical chemotherapy for superficial bladder cancer still justified?Superficial bladder cancer: part 2. Management.Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: time period-related comparison between Japan and Western countriesEvaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.Comparison of survival outcomes among cancer patients treated in and out of clinical trials.Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer.Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond.The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.Immunotherapy of bladder cancer.Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.Adjuvant intravesical therapy based on an in vitro cytotoxicity assay in the management of superficial transitional cell cancer of the urinary bladder.A Festschrift in Honor of Edward M. Messing, MD, FACS
P2860
Q24188046-11BDB6E2-27FE-4B6D-8EE5-657723F62506Q24247924-0A6A73B1-61B7-414D-A098-F461B3EC6B0CQ26739003-FBD29293-B8D1-4AFF-ACD3-E275042EFBFCQ26775772-C4BEA15D-EDC2-431D-9475-B59B0C1814CCQ27011829-D3312243-D7B6-4518-9AF9-202E44D79470Q31112248-5184C06A-8BC0-403F-B12A-467F34564685Q33284216-B5C5E349-6473-4816-985B-1723A07482B6Q34115106-5BE4156C-9DA9-4079-A7B2-D5EB228A8509Q35097994-5DFA5DB8-CDBB-4825-A09C-03BA70ED9339Q35685707-6D42BF98-6558-47B2-BEF9-7FBF10BB90F5Q36253605-781FACDA-62C9-43A9-98D1-F0C1616FDB45Q36788508-38886497-471B-43A8-9961-D6D7B434D9D1Q37403151-9449CCE5-FAC0-4B12-8C26-1B9899513EC9Q37471721-1BDE065C-A097-4FC2-925E-98906BF2364CQ37696178-29976487-DEE6-429E-AB6E-976B3C8C86F5Q37696455-AA298175-2B13-46F6-8676-D036C6EF1AD8Q37773294-4B653600-1804-48AA-9CF7-241FC3CD9139Q38091720-84F78555-2BEC-488E-92DE-1E80AFC5F791Q38425054-36E54182-9878-4B6E-B0EC-19F0AA06961EQ38684886-989A7193-43A4-4118-BA16-74E1ED71E7B0Q41564538-09AA29F9-9271-412B-83D2-651D1EA7254DQ46851166-A371A226-2722-4864-B958-3F10828B8254Q53248425-665A6F56-D9DD-4439-ACBD-9655035567EFQ58691149-4768D62F-7FD1-4221-8B47-AB44EBC8FD11
P2860
Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Randomized intergroup comparis ...... outhwest oncology group study.
@en
Randomized intergroup comparis ...... outhwest oncology group study.
@nl
type
label
Randomized intergroup comparis ...... outhwest oncology group study.
@en
Randomized intergroup comparis ...... outhwest oncology group study.
@nl
prefLabel
Randomized intergroup comparis ...... outhwest oncology group study.
@en
Randomized intergroup comparis ...... outhwest oncology group study.
@nl
P2093
P1433
P1476
Randomized intergroup comparis ...... outhwest oncology group study.
@en
P2093
Barton Grossman H
Blumenstein BA
Crissman JD
David Crawford E
Messing EM
Sagalowsky AI
Sarosdy MF
P304
P356
10.1016/1078-1439(95)00041-F
P577
1995-05-01T00:00:00Z